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Abstract
Background: Visual loss in glaucoma is associated with pathological changes in retinal ganglion cell (RGC) axons and a slow
decline in the RGC population. Age and elevated intraocular pressure (IOP) are the main risk factors for glaucomatous loss of
vision. Several studies have implicated the proinflammatory cytokine tumor necrosis factor- a (TNF-a) as a link between
elevated IOP and RGC death, but the cellular source of TNF-a and its causative role in RGC death remain uncertain. Here,
using a rat model of glaucoma, we investigated the source of elevated TNF- a and examined whether Etanercept, a TNF-a
blocker that is in common clinical use for other indications, is protective against RGC death.
Methodology/Principal Findings: Episcleral vein cauterization (EVC) caused intraocular pressure (IOP) to be elevated for at
least 28 days. IOP elevation resulted in a dramatic increase in TNF-a levels within a few days, axonal degeneration, and a
38% loss of RGCs by 4 weeks. Immunostaining coupled with confocal microscopy showed that OHT induced robust
induction of TNF-a in Iba-1-positive microglia around the optic nerve head (ONH). Despite persistent elevation of IOP,
Etanercept reduced microglial activation, TNF-a levels, axon degeneration in the optic nerve, and the loss of RGCs.
Conclusions/Significance: Ocular hypertension (OHT) triggers an inflammatory response characterized by the appearance
of activated microglia around the ONH that express TNF-a. Blocking TNF-a activity with a clinically approved agent inhibits
this microglial response and prevents axonal degeneration and loss of RGCs. These findings suggest a new treatment
strategy for glaucoma using TNF- a antagonists or suppressors of inflammation.
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Introduction
Retinal ganglion cell (RGC) death and subsequent visual field
defects that progress to blindness are the underlying pathophys-
iology of glaucoma [1]. Age is the leading risk factor, with elevated
intraocular pressure (IOP) being the only risk factor that can be
modified [2–4]. Lowering IOP with surgery or drugs reduces the
rate of optic nerve head (ONH) damage and progressive visual
field loss by almost half, firmly establishing IOP reduction as an
effective treatment for glaucoma. Proposed mechanisms linking
RGC loss to elevated IOP include a compressive effect on the
cribriform plates of the lamina cribrosa [5], pressure-induced
tissue ischemia [6,7], and local cellular response mechanisms [8].
Considerable evidence suggests that the damage begins within
the optic nerve due to structural changes within the lamina
cribrosa [9], leading to cellular changes that influence RGC
viability [10]. Histopathological studies of the glaucomatous ONH
reveal astrocyte and microglial activation accompanying neural
damage [11,12]. Activated microglia display an altered morphol-
ogy, producing cytotoxic and degenerative factors [13,14].
TNF-a is a proinflammatory cytokine that is secreted in
response to infection and trauma, and can lead to apoptosis in
susceptible cells through the activation of caspases [15] or
indirectly via activation of microglia [16]. TNF-a and its receptor
have been detected in the ONH of glaucoma patients [12,17,18]
and in a rat model of glaucoma [19], suggesting that TNF-a may
be an important factor in the neurodegenerative process of
glaucoma. Using a mouse model of glaucoma, we previously found
that TNF-a mediates the cytotoxic effect of ocular hypertension
(OHT) on RGCs through a mechanism that involves microglial
activation and loss of oligodendrocytes [20]. However, those
studies left open several questions, including the cellular source of
PLoS ONE | www.plosone.org 1 July 2012 | Volume 7 | Issue 7 | e40065TNF-a, whether the observed RGC loss was due to the particular
method of OHT induction that was used, whether the findings
would generalize to other species, and whether RGC loss could be
attenuated using clinically available treatments. Etanercept
(EnbrelH) is a decoy receptor consisting of the ligand-binding
domain of the TNF type II receptor and the Fc component of
human immunoglobulin G1. Etanercept competitively inhibits the
binding of free TNF-a and TNF-b to cell surface receptors, and is
used clinically for rheumatoid arthritis, juvenile idiopathic
arthritis, ankylosing spondylitis, and psoriatic arthritis [21,22]. In
rats with endotoxin-induced uveitis, subcutaneous injection of
Etanercept reduced the level of TNF-a and decreased intraocular
inflammation [23]. The aims in the present study were to examine
the expression of TNF-a in a rat model of chronic OHT,
determine the cellular localization of TNF-a, and evaluate
whether Etanercept would decrease TNF-a levels and reduce
optic nerve degeneration and RGC loss.
Results
Systemic Treatment with Etanercept does not Affect
Intraocular Pressure
We induced OHT in the right eyes of rats (n=40) by
cauterizing the episcleral vein, leaving the left eye as a control.
Whereas the average IOP in the control eye was
14.460.3 mm Hg, IOP rose to 47.6612.7 mm Hg immediately
after cauterization and remained elevated for the duration of the
study in 80% (n=32) of the eyes at 4 weeks after EVC; 12.5%
(n=5) fell into phthisis and 7.5% (n=3) did not meet the criteria
for successful OHT induction. In the OHT groups, Etanercept
(0.3 or 1.0 mg/kg) or saline was injected intraperitoneally three
times a week from the time of initial IOP elevation until the time of
euthanasia. Over the next 4 weeks, IOP remained stable at
approximately 2.2-fold above baseline in the group treated with
0.3 mg/kg Etanercept, 1.9 -fold in the group treated with 1.0 mg/
kg Etanercept, and 2-fold in the sham-operated control group;
these values did not differ from one another (Kruskal-Wallis test,
all P.0.05 at each time point: Fig. 1). Thus intraperitoneal
injection of Etanercept had no effect on IOP.
Detection of Etanercept in the Eye
Etanercept is a recombinant chimeric protein generated by
fusing the ligand-binding portion of human TNF- a receptor
TNFR-2 and the Fc portion of human IgG1. To investigate
whether intraperitoneally injected Etanercept reaches the retina,
we immunoprecipitated retinal lysates treated with Etanercept or
normal saline with an antibody against human IgG1. The
immunoprecipitate from animals treated with Etanercept con-
tained one strong band at the appropriate size that was absent in
immunoprecipitates from mice receiving normal saline (Fig. S1).
TNF-a Levels Increase with OHT
Previous studies have reported elevated levels of TNF-a in the
retina and ONH of glaucoma patients [11,12,17,24]. We
investigated whether this elevation could be detected in the
present rat model by measuring TNF-a levels by ELISA in retinal
lysates. The ELISA results are normalized by the level of protein
per retina. ELISA showed that the level of TNF-a increased 3.9-
fold three days after OHT induction relative to sham-operated
control rats and continued to rise. Seven days after OHT
induction, TNF-a levels were 1.060.5 pg/mg, approximately 17
times higher than in sham-operated control rats. Levels declined
thereafter but remained elevated for at least 4 weeks. Treatment
with 0.3 mg/kg of Etanercept reduced the level of TNF-a 7 days
after treatment initiation (Mann-Whitney U test, P=0.001), and
the higher dose (1.0 mg/kg) led to an even stronger reduction
(Mann-Whitney U test, P,0.001: Fig. 2A). Western blot analysis
confirmed the elevation of TNF-a 14 days after the induction of
OHT and the reduction in TNF-a after Etanercept treatment
(0.3 mg/kg, Fig. 2B).
Cellular Source of TNF-a
To identify the source of TNF-a, we carried out immunostain-
ing on retinal whole-mounts. Immunostaining with the Iba-1
antibody revealed differences in the appearance of microglia in the
ONH area 5 days after OHT induction. Microglial activation is
characterized by morphological changes such as swelling of the
cell body, thickening of the proximal processes, and a reduction of
distal ramifications [25]. In control eyes with sham surgery, most
Iba-1-positive cells were stage 1 resting microglia, with very few
stage 3 and 4 cells around the ONH (28.362.6 cells/mm
2:
Fig. 3A). With OHT, we observed increased numbers of stage 3
and 4 microglia with round-shaped cell bodies and thick, stout
processes or no processes at all around the ONH (167.8610.3
cells/mm
2, Mann-Whitney U test, P,0.001: Fig. 3B). Etanercept
treatment resulted in a 53% decrease in the number of infiltrative
stage 3 and 4 microglia around the ONH compared to untreated
OHT rats (7869 cells/mm
2, Mann-Whitney U test, P,0.001:
Fig. 3C, D).
We also carried out confocal microscopy on tissue double-
labeled with antibodies against microglia (Iba-1) and astrocytes
(GFAP). In sham-operated (control) retinal whole-mounts, we
observed resting microglia with ramified processes distributed in a
Figure 1. Etanercept does not affect intraocular pressure (IOP)
after episcleral vein cauterization (EVC). EVC increases IOP over a
4-week period, and Etanercept does not block this increase at either 0.3
or 1.0 mg/kg (n=10 rats for each time point).
doi:10.1371/journal.pone.0040065.g001
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cells and minimal GFAP expression (Fig. 4C, C9). Five days after
OHT induction, increased numbers of microglia were found
around the ONH along with increased expression of the astrocyte
marker, GFAP (Fig. 4F). Iba-1-positive microglia were mostly
amoeboid-shaped and were double-stained with antibodies to
TNF-a (Fig. 4F9). Etanercept prevented the infiltration of
amoeboid-shaped microglia and GFP expression. In addition,
few Iba-1-positive microglia showed TNF-a staining in Etaner-
cept-treated eyes (Fig. 4I9).
Etanercept Prevents Pathologic Changes in the Optic
Nerve
We next compared axon morphology and density in cross-
sections through the optic nerve. After 28 days of elevated IOP,
the nerve showed marked axonal disorder compared to sham-
operated controls, with a heterogeneous caliber of myelinated
axons, increased vacuolization, and ballooning (Fig. 5B).
Etanercept prevented this degeneration, resulting in an appear-
ance similar to that of the control nerves (Fig. 5C). In terms of
total axons, the axon density in sham-operated control nerves
was 62,553612,966 axons/mm
2, and this number decreased by
40.2% in OHT eyes (Mann-Whitney U test, P,0.001).
Etanercept (0.3 mg/kg) maintained axon density at considerably
higher levels than were seen in saline-treated controls (Mann-
Whitney U test, P=0.001: Fig. 4D) with only minor degener-
ative changes. We next examined the morphology of axons by
transmission electron microscopy (TEM). The normal sham-
operated optic nerve shows a compact arrangement of
myelinated axons (Fig. 6A, D). With OHT, the major change
was the appearance of swollen axons (Fig. 6B, arrowhead) with
occasional cytoskeletal disintegration (Fig. 6E, asterisk) and
loosely organized myelin with multilayered, whorled masses
(Fig. 6B, arrow). Axons in the optic nerves of Etanercept-treated
OHT rats appeared nearly normal (Fig. 6C, F).
Figure 2. Etanercept suppresses TNF-a elevation following IOP elevation. A, ELISA for TNF-a protein in the retina. Mann-Whitney U test,
*P,0.05, **P,0.01 comparing sham-operated control and vehicle-treated OHT;
{P,0.05,
{{P,0.01 comparing OHT rats treated with vehicle vs.
Etanercept (n=6 for each group at each time point). B, Western blot analysis of TNF-a 14 days after OHT induction with and without Etanercept (n=4
for each group). OHT, Ocular hypertension; Etan., Etanercept.
doi:10.1371/journal.pone.0040065.g002
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PLoS ONE | www.plosone.org 3 July 2012 | Volume 7 | Issue 7 | e40065Figure 3. Activation of microglia in the vitreal surface of the optic nerve head (ONH). A, Iba-l positive microglia in sham-operated control
eyes are ramified and quiescent and exhibit a mosaic arrangement around ONH. B, Increased number of activated microglia with short, broad
processes 5 days after OHT induction. C, Decreased number of active microglia around the ONH with Etanercept treatment. D, Bar graph indicating
the number of stage 3 and 4 Iba-1 positive microglia/mm
2. Mann-Whitney U test, **P,0.01 comparing sham-operated control and OHT cases treated
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To examine changes in proteins associated with the axonal
cytoskeleton, we performed western blot analysis and immuno-
histochemical staining to detect the light- and medium chains of
neurofilaments (NF-L, NF-M, respectively). In the retina, both
NF-L and NF-M antibodies stained axon fascicles around the
ganglion cell layer (Fig. 7A). Protein analyses show that expression
of both NF-L and NF-M decreased 14 days after induction of
OHT, whereas Etanercept maintained the expression of both
proteins close to normal levels (Fig. 7B–E).
Etanercept Prevents Retinal Ganglion Cell Loss with OHT
We next investigated whether elevation of IOP leads to the
hallmark feature of glaucoma, a loss of RGCs, in the current
model [26–28]. In the sham-operated control group, the number
of RGCs visualized in retinal whole-mounts (Fig. 8A) that were co-
labeled with both TUJ1 and NeuN was 2004.4640.4 per mm
2,
whereas the number in OHT retinas treated only with saline was
38% lower (Fig. 8B, Mann-Whitney U test, P,0.001). Etanercept
at either 0.3 or 1.0 mg/kg prevented this decrease and maintained
the number of RGC at near-normal levels (Fig. 8B, Mann-
Whitney U test, P,0.001 for either dosage compared to saline-
treated OHT controls).
Discussion
The current study confirms and extends previous findings
linking retinal ganglion cell (RGC) loss in glaucoma to TNF-a.
Our results demonstrate this link using a different method to
induce ocular hypertension (OHT) and a different species than our
earlier study, while for the first time identifying microglia at the
optic nerve head (ONH) as the source of TNF-a. In addition, we
show that Etanercept (EnbrelH), a widely used TNF-a antagonist,
attenuates inflammation and RGC loss.
In the present study, we elevated intraocular pressure (IOP)
by episcleral vein cauterization (EVC), which led to axon
degeneration in the optic nerve and eventual loss of RGCs.
Elevated IOP caused levels of TNF-a to increase within 3 days,
and by 7 days, levels were 17-fold higher than normal and
remained elevated for at least 4 weeks. However, compared to
proinflammatory eye disease such as experimental uveitis
induced by lipopolysaccharide [29], the level of TNF-a is much
lower in our model. Nevertheless, along with the increases of
TNF-a in our studies, we observed a massive expansion of the
macrophage/microglial population around the ONH after 5–7
days. This change is consistent with our previous proposal that
the cytotoxic effect of OHT-induced TNF-a might be mediated
by CD11b+ microglia in a mouse model of chronic OHT [20].
However, the previous study left several major questions
unanswered. One limitation of that study was the use of
laser-induced angle closure to elevate OHT, which could have
caused an inflammatory response and an increase in proin-
flammatory cytokines, including TNF-a, as a result of 100
confluent laser spots on the corneal limbus. By using three-point
episcleral vein cauterization, we minimized the inflammatory
effect associated with the model itself. Secondly, in the previous
study we investigated the role of TNF-a using genetically
altered mouse strains and immunodepletion. The present study
brings us closer to clinical translation by showing that
Etanercept, an agent that is already in wide clinical use for
with vehicle or Etanercept;
{{P,0.01 comparing OHT cases treated with vehicle vs. Etanercept. Data are expressed as the mean 6 SEM (n=6 for each
group). Original magnification, 68 (A–C); Scale bar, 100 mm. OHT, ocular hypertension; Etan., Etanercept 1.0 mg/kg.
doi:10.1371/journal.pone.0040065.g003
Figure 4. Confocal images of immunofluorescent staining for Iba-1 (green), TNF-a (red), and GFAP (cyan). Merged image demonstrates
the colocalization of TNF-a and Iba-1 (C, F, I). Square insets show enlargements of selected cells (C’, F’, and I’). Original magnification:610 (A–H),663
(A9–H9); Scale bars: 100 mm at lower magnification, 25 mm at higher magnification.
doi:10.1371/journal.pone.0040065.g004
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induced death. Since maintaining elevated IOP is crucial in any
model of glaucoma, Etanercept was given systemically rather
than intravitreally, and did not affect IOP (Fig. 1). Another
technical issue is that cauterizing the episcleral vein may lead to
retinal ischemia, which can also result in RGC death [30,31].
Ischemia and hypoxia have been implicated in the development
of RGC death in patients with glaucoma [18,32], and thus the
model of chronic OHT used here may mimic multiple features
of the clinical disorder.
Retinal microglia are resident macrophages derived from
myeloid progenitor cells that are capable of phagocytic activity
in multiple conditions [33,34] that include aging, hypoxia,
neurodegeneration, and injury. In all of these instances, microglia
transform from a resting state with a ramified morphology to an
activated phenotype [35] that retract their processes and exhibit a
rounded cell body. Iba-1 antibody is a microglial/macrophage
marker that is expressed in both the resting and activated states
[36]. Immunohistochemical staining on whole-mounts showed
increased numbers of amoeboid, activated Iba-1-positive microglia
Figure 5. Etanercept prevents optic nerve degeneration after OHT induction. A–C, High magnification light micrographs of cross sections
through rat optic nerve. EVC leads to diminished axon density, enlarged axons (white arrowhead), and degenerating axon profiles (black arrow in B).
D, Bar graph showing axon densities in the various groups. Data are expressed as the mean 6 SEM. Mann-Whitney U test, **P,0.01 compared
between sham-operated control and vehicle-treated OHT,
{{P,0.01 comparing OHT cases treated with vehicle vs. Etanercept (n=6 for each group).
Original magnification: 6100; Scale bar, 5 mm. OHT, Ocular hypertension; Etan., Etanercept.
doi:10.1371/journal.pone.0040065.g005
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the mosaic distribution of ramified ‘‘resting’’ microglia seen in
sham-operated control retinas (Figs. 3A, 4A). It is possible that
elevated IOP with subsequent hypoxia may break down the blood-
retina-barrier at the ONH [37–39] or cause local stress at the
ONH [40], eliciting a strong inflammatory and glial response. Our
colocalization studies indicate that Iba-1-positive microglia located
around the ONH are the likely source of TNF-a seen after OHT
(Fig. 4D–F). In Alzheimer’s disease (AD), microglia are activated at
sites of neuronal degeneration [41]. Co-culture of amyloid b
protein with activated microglia produces TNF-a [42] and chronic
neuronal TNF-a expression in an AD mouse model, and results in
neuronal cell death [43], suggesting that microglia are the source
of TNF-a. However, the source of TNF-a in the eye has been
controversial. Although it is widely acknowledged that increased
IOP can trigger an inflammatory response involving the ONH
area [11,20,44], various reports have suggested that glial cells
[8,45], astrocytes [46] and Mu ¨ller cells [47] are the source of TNF-
a. Here, OHT induction resulted in extensive microglia and
astrocyte activation as visualized with Iba-1 and GFAP staining,
respectively. However, TNF-a colocalized only with microglia,
and not with either astrocytes or Mu ¨ller cells (data not shown) 5
days after EVC. Since TNF-a was seen to be elevated from day 3
onwards after OHT induction, it is possible that astrocytes and
Mu ¨ller cells may express cytokines and chemokines at an earlier
point that lead to microglial activation and further enhancement
of the neural injury. Microglial activation and clustering at the
ONH and central retina have been shown to be early events,
rather than late consequences, of RGC degeneration in another
animal model of glaucoma [48]. The morphology of Iba-1 positive
microglia changes to an activated phenotype as early as 3 days
after IOP elevation [49], and our results of elevated expression of
TNF-a on or before day 3 (Fig. 2B) implicates microglia as the
major source of TNF-a expression after OHT. This is also
supported by studies by Kreutz et al. [50] who demonstrated that
in response to optic nerve crush injury, macrophages are recruited
to the optic nerve and their phagocytic activity is accompanied by
demyelination of RGC axons, which was abolished with the
blockade of TNF-a signaling. Another recent study [51] showed
that soluble TNF- a production from microglia is required for the
death of co-cultured dopaminergic neurons, and that Etanercept
could attenuate cell death without affecting other possible effects of
microglia. In our previous study, we showed that the effect of
TNF-a on RGC death is indirect and is dependent upon TNFR2-
mediated activation of microglia [20]. In addition, other studies
have shown that FasL, a TNF family member, is upregulated in
Figure 6. Etanercept prevents axon degeneration after IOP elevation. A, D, Electron micrograph showing normal compact axoplasm and
myelination in sham-treated control optic nerve. B, E, Axonal swelling with separation of myelin sheath (black arrowhead), degraded collection of
altered tubulovesicular structures (E, asterisk), and a whorl-shaped mass (C, black arrow). C, F, Normal-appearing axons in OHT rat treated with
Etanercept. Original magnification: 63400 (A–C), 65800 (D–F); Scale bar, 5 mm. OHT, Ocular hypertension; Etan., Etanercept.
doi:10.1371/journal.pone.0040065.g006
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PLoS ONE | www.plosone.org 8 July 2012 | Volume 7 | Issue 7 | e40065Figure 7. Etanercept prevents the loss of cytoskeletal proteins following OHT induction. A, Immunohistochemical staining for
neurofilament light chain (NF-L) and middle chain (NF-M) proteins around the ganglion cell layer. Western blot analysis for NF-L (B) and NF-M (C) after
OHT in rats treated with or without Etanercept (n=4 in each lane). Differences in loading were normalized by the level of b-actin. Bar graphs
indicating relative levels of NF-L (D) and NF-M (E)t ob-actin by densitometry, reflecting the results from four independent experiments. Mann-
Whitney U test, **P,0.01 comparing sham-operated control and vehicle-treated OHT;
{{P,0.01 comparing OHT rats treated with vehicle vs.
Etanercept. Original magnification :620, Scale bar, 100 mm. OHT, Ocular hypertension; Etan., Etanercept; NF-L, neurofilament-L; NF-M, neurofilament-
M.
doi:10.1371/journal.pone.0040065.g007
Figure 8. Etanercept prevents the loss of RGCs following OHT induction. A, Flat-mounted retina double immuno-labeled with TUJ-1 and
NeuN antibodies to visualize RGCs and their axons. OHT resulted in a loss of RGCs (b) that was prevented with Etanercept (c, d). B, Bar graph showing
quantitation of RGC survival. Data are expressed as mean 6 SEM; n=10 at each time point. Kruskal-Wallis test, **P,0.01 comparing three groups (A),
Mann-Whitney U test, *P,0.05, **P,0.01 comparing sham-operated control and vehicle-treated OHT;
{{P,0.01 comparing OHT treated with vehicle
vs. Etanercept. NeuN (red), b-tubulin (green), Original magnification: 620; Scale bar, 50 mm. OHT, ocular hypertension; Etan., Etanercept.
doi:10.1371/journal.pone.0040065.g008
Etanercept Prevents Glaucomatous Neurodegeneration
PLoS ONE | www.plosone.org 9 July 2012 | Volume 7 | Issue 7 | e40065microglia in the glaucomatous retina [52], and that the
membrane-bound form of FasL acts as a key effector of RGC
death downstream from TNF- a elevation [53].
Another finding in our study was the early dramatic decrease in
retinal levels of NF-L and NF-M 14 days after OHT induction
(Fig. 7), which preceded the loss of RCGs at day 28 (Fig. 8). These
findings are consistent with earlier studies showing that axonal
dysfunction precedes neuronal loss [54]. The effect of TNF-a
inhibition in maintaining near-normal levels of neurofilament and
RGCs in rats with OHT suggests that Etanercept may protect
axons and secondarily RGC somata even in the presence of
persistent ocular hypertension.
In conclusion, our results suggest that elevation of the pro-
inflammatory cytokine TNF-a and ONH inflammation play an
important role in linking elevated intraocular pressure to the loss of
optic nerve axons and RGCs that are the hallmark features of
glaucoma (Fig. 9). Lowering of IOP is currently the most effective
clinical approach to reducing the progression of glaucomatous
visual loss [55,56]. However, some patients continue to lose vision
despite lowering of IOP, suggesting the need for adjunct
treatments. The present results, supported by considerable
evidence from other studies, suggest that Etanercept or other
TNF- a antagonists or suppressors of inflammation should be
considered as an adjunct therapy in the treatment of glaucoma.
Materials and Methods
Animals
All animal experiments followed the guidelines of the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research and were approved by the Animal Care Committee of
The Massachusetts Eye and Ear Infirmary. Male Brown Norway
rats (8–10 weeks) were purchased from Charles River Laboratories
(Wilmington, ME). A total of 140 rats between 200 and 300 g
weight were used. Animals were housed under a 12-h light/dark
cycle with free access to water and food. For general anesthesia, a
mixture of ketamine (100 mg/kg; Phoenix Scientific, St. Joseph,
MO) and xylazine (10 mg/kg; Phoenix Scientific) was adminis-
tered intramuscularly.
Experimental Ocular Hypertension
Chronic ocular hypertension (OHT) was induced in the right
eye (total n=140) by episcleral vein cauterization (EVC) according
to published procedures with minor modifications [57,58]. Briefly,
after animals were deeply anesthetized, an incision was made
through the conjunctiva and Tenon’s capsule on the limbal
periphery. The episcleral veins in the right eye were identified by
their location in relation to the extraocular muscles; three of them
(two dorsal veins and one temporal ventral vein) were cauterized
with a hand-held ophthalmic cautery (Electric Eye Cautery,
Rumex International Co., St. Petersburg, FL) under a surgical
microscope. The left eye received sham surgery (conjunctival
incisions without cauterization). Successful OHT was defined as
intraocular pressure (IOP) elevation greater than 30% of baseline
IOP and no cauterization-associated complications after EVC.
Measurement of Intraocular Pressure
IOP was measured in both eyes with the TonoLab tonometer
TV02 (Helsinki, Finland) with rats under topical anesthesia with
0.5% proparacaine hydrochloride eye drops. IOP was measured
before EVC, immediately after cauterization, and then on days 1,
7, 14, 21, and 28. The TonoLab acquires six valid rebounds of the
device from the eye and takes the mean of the middle four readings
to make one summary measurement. The instrument indicates the
reliability of the reading by the position of a bar next to the
reported value. A single set of readings was collected with the best
reproducibility indicator (no bar) at each time point during the IOP
measurements. Rats were excluded from further analysis if the peak
IOP was ,6 mm Hg above baseline or if the treated eye developed
corneal ulceration, hyphema, or other ocular pathology. In total,
13 rats were excluded based on these criteria.
Treatment with a Soluble TNF-a Receptor
Etanercept, a soluble 75 kDa TNF-a receptor/Fc fusion protein
(EnbrelH, Amgen, Thousand Oaks, CA, USA), was reconstituted
with sterile water according to the manufacturer’s instructions.
Rats were separated into three groups. Starting one day after
induction of chronic glaucoma, two groups (n=10 each) were
given subcutaneous injection of Etanercept at either 0.3 mg/kg or
Figure 9. Schematic illustration of retinal ganglion cell (RGC) death following elevation of intraocular pressure (IOP). A, Ramified
quiescent microglia in eyes with normal IOP. B, Elevated IOP leads to increased numbers of activated microglia with amoeboid morphology around
the optic nerve head. These microglia appear to secrete TNF-a leading to RGC death. Other molecules, including FasL on microglia, nitric oxide (NO),
and reactive oxygen species (ROS) may also play a role in RGC death.
doi:10.1371/journal.pone.0040065.g009
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group (n=10) received intraperitoneal injection of physiological
saline three times a week. These doses were selected based upon
previous studies that demonstrated the effectiveness of the drug in
other disease models [59–61].
Retinal Immunohistochemistry
For retinal cryosection immunostaining, sections through the
retina (10 mm) with the optic nerve attached were pre-blocked
(PBS containing 10% goat serum, 0.5% gelatin, 3% BSA, and
0.2% Tween-20) and then incubated with rabbit anti-Iba-1
antibody (1:500; Wako Chemicals USA Inc., Richmond, VA) as
a marker for microglia, anti-neurofilament light chain monoclonal
antibody (1:1000; Thermo Scientific), and/or anti-neurofilament
middle chain monoclonal antibody (1:1000; Cell Signaling
Danvers, MA) overnight at 4uC. Alexa Fluor 488-conjugated goat
anti-mouse IgG (Invitrogen, Carlsbad, CA) or Alexa Fluor 546-
conjugated donkey anti rabbit IgG (Invitrogen) were used as
secondary antibodies and incubated at room temperature for 1
hour prior to mounting in Vectashield mounting medium (Vector
Laboratories, Burlingame, CA).
For whole-mount immunostaining, rat eyes were enucleated
immediately after transcardiac perfusion. Post-fixed retinas were
washed several times in fresh PBS, transferred to multi-well plates,
and blocked in 10% normal goat serum (Sigma-Aldrich, St. Louis,
MO) with 0.5% Triton X-100 in 0.1 ml PBS overnight. The retinas
werethenincubatedinthesamemediumcontainingantibodyTUJ1
(1:500;mouseanti-neuronalclassIIIb-Tubulin,Covance,Berkeley,
CA), anti-NeuN (1:500; made in mouse, clone A60, Chemicon,
Temecula, CA), mouse monoclonal antibody to TNF-a (1:200;
Abcam,Cambridge,MA),and/orrabbitanti-Iba-1antibody(1:500;
Wako Chemicals USA Inc., Richmond, VA) for 1 day at 4uCo na
shakingplatform.Afterthreefurtherwashes,retinaswereincubated
withagoatantibodytomouseIgGconjugatedtoAlexaFluor546and
a donkey antibody to rabbit IgG conjugated to Alexa Fluor 488
dilutedinblockingmedium(1:400;Invitrogen)overnightat4uCand
flat-mounted onto slides after making four radial slits and cover-
slipped inVectashield mounting medium.
Assessment of RGC Survival
Surviving RGCs were quantified in retinal whole mount
preparations that were double-immunolabeled with the TUJ1
antibody directed against bIII tubulin and anti-NeuN. Within the
ganglion cell layer, bIII tubulin is expressed only in RGCs, and
thus immunostaining for this antigen can be used to distinguish
RGCs from the many amacrine cells that are also in this layer
[62,63]. TUJ1- and NeuN-immunofluorescent cells in the
ganglion cell layer were visualized with a Zeiss LSM 510 META
laser scanning confocal microscope using a 206 objective and
were counted manually in eight confocal fields in each quadrant of
the retina using ImageJ software and the cell counter plugin. We
counted four fields in the center near the ONH and four in the
periphery, and then averaged the 32 counts for each retina to
obtain RGCs per mm
2.
Assessment of Optic Nerve Axon Survival
RGC axons were quantified in the retrobulbar optic nerve
10 mm from the globe under light microscopy. At least three
sections were used from each of six rats for each condition. Optic
nerves were placed immediately into fixative consisting of 2.5%
glutaraldehyde and 2% formaldehyde in 0.1 M cacodylate buffer
with 0.08 M CaCl2 overnight at 4uC. The tissue was washed in
0.1 M cacodylate buffer and postfixed in 2% aqueous OsO4.
Segments were dehydrated in graded alcohols and embedded in
Epon. One-micron sections were cut and stained with 1%
toluidine blue in 1% borate buffer. Five regions from each section
were chosen for quantitation of axon density. In brief, 1006
photomicrographs of each section were collected using an
Olympus Povis AX70 microscope (Olympus Optical, Tokyo,
Japan). Axons were counted semi-automatically with a method
described previously [64]. The entire surface area of the nerve was
represented in each sample and axon density was calculated as the
mean across the random micrographs. Measurements of the cross-
sectional area of each nerve were combined with axon density to
estimate the total number of axons per nerve.
Evaluating Microglial Activation
Using whole-mounted retinas, we classified the activation of
Iba-1-positive microglia as described [25] using four stages. Stage
1 are resting microglia, which have rod-shaped somata with fine,
ramified processes; Stage 2 are activated ramified microglia with
elongated cell bodies and long, thicker processes; Stage 3 are
amoeboid microglia with a round-shaped cell bodies and short,
thick, stout processes; Stage 4 are phagocytic cells with round-
shaped somata, vacuolated cytoplasm, and lacking any processes
observed at the light microscopic level. In all whole-mounts,
photos were taken at 86 magnification with the ONH in the
center. The numbers of Iba-1 positive cells with the characteristics
of stage 3 or 4 activation were counted manually in individual
confocal fields using NIH ImageJ software and the cell counter
plugin.
Colocalization of TNF-a and Microglia
Retinal microglia and astrocytes were visualized in retinal
whole-mounts by immunostaining with antibodies directed against
Iba-1 and GFAP as previously described. The antibody to TNF-a
was used for colocalization studies as specified in the manufactur-
er’s recommendations. Whole-mounts were visualized using a
Leica SP5 confocal microscope with 106and 636objectives. The
fluorescence of individual fluorochromes was captured separately
in sequential mode (diode 405, argon 488, HeNe 543, HeNe 633)
after optimization to reduce bleed-through between channels using
Leica software. A stack of optical sections was taken at intervals of
0.16 mm.
Western Blot Analysis
Retinas from experimental eyes with chronic OHT and
control eyes were dissected from the RPE-choroid at designated
time points after EVC. Samples were separated electrophoret-
ically on NuPAGE 4–12% Bis-Tris Gels (Invitrogen) and
transferred onto PVDF membrane (0.45 mm; Millipore, Bill-
erica, MA). After blocking with 3% nonfat dried milk,
membranes were incubated overnight with a primary antibody
against TNF-a (1:100, Cell Signaling, Danvers, MA), neurofil-
ament light chain (monoclonal antibody, 1:1000; Thermo
Scientific), and neurofilament middle chain (monoclonal anti-
body, 1:1000; Cell Signaling). The blotted membranes were
then incubated for 30 min at room temperature with an HRP-
conjugated secondary antibody directed against rabbit IgG
(1:10,000; Jackson ImmunoResearch). Immunoreactive bands
were visualized by enhanced chemiluminescence (ECL) and
exposed onto Fuji RX film (Fuji-Film, Tokyo, Japan).
Co-immunoprecipitation
To investigate whether we could detect Etanercept in the rodent
retina, immunoprecipitation (IP) was performed as previously
described. [65] Briefly, C57BL/6 mice (n=2) received a single
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nized 24 hours later, perfused with PBS, and retinas were isolated
under a dissecting microscope. Control mice (n=2) received an
equal volume of normal saline (N/S). Retinas from each group
were pooled in 0.5 ml chilled lysis buffer and homogenized with a
tissue grinder. Supernatants were collected after centrifugation at
15,000 rpm for 10 min at 4uC. Protein concentrations were
determined by Bio-Rad protein assay (Hercules, CA). Equal
amounts (500 mg) of the retinal lysates were incubated overnight at
4uC with 20 ml of protein A/G agarose beads (Protein A/G Plus;
Pierce, Thermo Scientific). The beads were then washed seven
times with chilled lysis buffer and immunopellets were separated
by SDS-PAGE and transferred onto PVDF membranes, where
they were probed overnight at 4uC with a mouse anti-human IgG1
Fc region antibody (R&D Systems). Membranes were then
incubated with an HRP-conjugated donkey anti-mouse secondary
antibody (Jackson Immunoresearch), developed with ECL, and
exposed to Fuji RX autoradiographic film.
ELISA Analysis for TNF-a
The tissue complex containing the vitreous and neural retina
was collected at 3, 7, 14, 21, or 28 days after EVC. Proteins were
extracted from each retina individually in 200 ml PBS containing a
protease inhibitor mixture (Complete, Roche Diagnostics, Plea-
santon, CA) and sonicated (10 W, 5 s, 4uC; Sonifier 250, Branson,
Danbury, CT). The supernatant was collected after centrifugation
at 14,0006g for 20 min at 4uC (Micromax RF, IEC, Needham
Heights, MA), and the total protein concentration was measured
with the DC protein assay kit (Bio-Rad, Hercules, CA). The level
of TNF-a was determined with rat TNF-a enzyme-linked
immunosorbent assay (ELISA) kits (R&D Systems) according to
the manufacturer’s protocols with slight modification. TNF-a
standards were reconstituted down to 1.5625 pg/ml. The absor-
bance at 450 nm was measured using a 96-well plate spectropho-
tometer (Spectramax 190, Molecular Devices, Sunnyvale, CA).
Absorbance values were converted to TNF-a concentration by
comparison with a simultaneously generated standard curve and
then normalized by the level of protein per retina. Standard curves
showed an R
2 value .0.98, demonstrating the sensitivity and
reliability of the method.
Statistical Analysis
Results are expressed as mean values 6 standard error of mean
(SEM). Statistical analysis was performed nonparametrically using
Mann-Whitney U-test and Kruskal-Wallis tests (SPSS Statistics
17.0, Chicago, IL). A p-value of less than 0.05 was considered
statistically significant.
Supporting Information
Figure S1 Immunoprecipitation of Etanercept from
retinal lysates. Five hundred mg of retinal lysate was incubated
with anti-human IgG1 antibody and protein A/G agarose beads.
Etanercept and mouse IgG were used as a positive control. Mice
treated with Etanercept showed immunoprecipitation of Etaner-
cept, whereas control mice did not. OHT, ocular hypertension;
Etan., Etanercept.
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